BASF Enters €664 million Deal to Acquire Pronova and Strengthen Omega 3 Business
date:Nov 22, 2012
a-3 fatty acids. Pronovas active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega-3 fatty acids, for example, in the areas of cognitive development or heart health.

The acquisition will be financed by way of available resources of BASF. The offer will be made by BASFs wholly-owned
5/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/26 11:06